% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{TauzideEspariat:271000,
author = {A. Tauziède-Espariat and E. Uro-Coste and P. Sievers$^*$
and Y. Nicaise and C. Mariet and A. Siegfried and G. Pierron
and D. Guillemot and J. Benzakoun and J. Pallud and M.
Roques and F. Bonneville and D. Larrieu-Ciron and P. Chaynes
and R. Saffroy and J. Hamelin and L. Hasty and A. Métais
and F. Chrétien and M. Kool$^*$ and J. Gojo and P. Varlet},
collaboration = {RENOCLIP-LOC},
title = {{CNS} tumor with {EP}300::{BCOR} fusion: discussing its
prevalence in adult population.},
journal = {Acta Neuropathologica Communications},
volume = {11},
number = {1},
issn = {2051-5960},
address = {London},
publisher = {Biomed Central},
reportid = {DKFZ-2023-00353},
pages = {26},
year = {2023},
abstract = {The Central Nervous System (CNS) tumor with BCOR internal
tandem duplication (ITD) has recently been added as a novel
embryonal histomolecular tumor type to the 2021 World Health
Organization (WHO) Classification of CNS Tumors. In
addition, other CNS tumors harboring a BCOR/BCORL1 fusion,
which are defined by a distinct DNA-methylation profile,
have been recently identified in the literature but
clinical, radiological and histopathological data remain
scarce. Herein, we present two adult cases of CNS tumors
with EP300::BCOR fusion. These two cases presented
radiological, histopathological, and immunohistochemical
homologies with CNS tumors having BCOR ITD in children. To
compare these tumors with different BCOR alterations, we
performed a literature review with a meta-analysis. CNS
tumors with EP300::BCOR fusion seem to be distinct from
their BCOR ITD counterparts in terms of age, location,
progression-free survival, tumor growth pattern, and
immunopositivity for the BCOR protein. CNS tumors from the
EP300::BCOR fusion methylation class in adults may be added
to the future WHO classification.},
subtyp = {Review Article},
keywords = {Child / Adult / Humans / Prevalence / Central Nervous
System Neoplasms: genetics / Biomarkers, Tumor: analysis /
Proto-Oncogene Proteins: genetics / Proto-Oncogene Proteins:
metabolism / Repressor Proteins: genetics / E1A-Associated
p300 Protein: genetics / Adult (Other) / BCOR (Other) /
EP300 (Other) / Biomarkers, Tumor (NLM Chemicals) / BCOR
protein, human (NLM Chemicals) / Proto-Oncogene Proteins
(NLM Chemicals) / Repressor Proteins (NLM Chemicals) / EP300
protein, human (NLM Chemicals) / E1A-Associated p300 Protein
(NLM Chemicals)},
cin = {B300 / HD01 / B062},
ddc = {610},
cid = {I:(DE-He78)B300-20160331 / I:(DE-He78)HD01-20160331 /
I:(DE-He78)B062-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:36782314},
pmc = {pmc:PMC9926824},
doi = {10.1186/s40478-023-01523-y},
url = {https://inrepo02.dkfz.de/record/271000},
}